AstraZeneca 2Q08 2Q Revenues: $8.0 billion (+9%, +2% at Constant Exchange Rate) 2Q Earnings: $1.6 billion (+13%, +6% CER) YTD Revenues: $15.6 billion (+10%, +3% CER) YTD Earnings: $3.1 billion (+4%, -3% CER) Comments: Sales were buoyed by 35%/27% growth in Crestor, which reached $916 million in 2Q08. Toprol sales plummeted 55%/58% in the quarter, while Nexium sales plateaued at $1.3 billion. Symbicort sales rose 25%/12% to $518 million and Pulmicort was up 20%/14% to $383 million....